Aberman Zami

Avg. Two Year Performance

(16%) Avg. Purchase Return
(8%) Compound
53% Avg. Sale Return
24% Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return4%(8%)2%(12%)(16%)
Purchase Success Rate2 of 72 of 74 of 72 of 71 of 7
Average Sale Return9%19%23%29%53%
Sale Success Rate3 of 32 of 32 of 33 of 32 of 3

Pluristem Therapeutics, Inc.

Drugs » Biotechnology

Director:

Holdings: 1.63M shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--